Alamar Biosciences, Inc. (ALMR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-22

Key Insights

Multiple Qiming-affiliated venture capital funds converted their preferred stock holdings into common and Class B common stock on 04/20/2026, indicating Alamar Biosciences completed its initial public offering on this date.
The conversion involved substantial share quantities across Series A-3, A-4, B, and C preferred stock, with aggregate Class B common stock holdings reaching approximately 10.595 million shares post-conversion, reflecting significant institutional investor stakes.
All reporting persons are based in the Cayman Islands and hold indirect beneficial ownership through various fund structures, demonstrating typical venture capital fund investment architecture in biotech companies.
The filing shows a structured preferred-to-common conversion at IPO rather than insider trading activity, with no price information provided for the conversion transactions, which is standard practice for equity reorganizations.

Want the newest filings?

This analysis covers the filing from 2026-04-22. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-20

Director Nicholas Naclerio received significant equity compensation including 5.5M+ shares of common stock acquired through conversion of preferred shares and convertible notes, indicating substantial post-IPO stake in Alamar Biosciences.
The filing documents the automatic conversion of multiple series of preferred stock (A-3, A-4, B, and C) into common stock upon IPO closing on 04/20/2026, representing a major corporate restructuring event.
Naclerio holds securities indirectly through two Illumina Innovation Fund entities (IIF II and IIF III), where he serves as sole managing member, suggesting institutional venture capital backing and potential ongoing investment relationship with Illumina.
The reporting person received equity incentive grants including 25,599 stock options at $17 strike price (vesting through 2029) and 5,686 RSUs, demonstrating alignment with long-term company performance post-IPO.

Filed: 2026-04-20

CFO Justin McAnear received a significant equity grant package including 37,220 RSUs and 1,141,438 stock options across two tranches, indicating substantial compensation alignment with company performance post-IPO.
The stock option grants with exercise prices of $17.00 and $4.62 suggest the company's IPO valuation or recent trading prices; the Class B to Common Stock reclassification confirms recent completion of the IPO process.
All equity grants include standard vesting schedules (25% cliff after 1 year, then monthly vesting over 4 years), reflecting typical retention mechanisms for executive leadership during the critical post-IPO period.
The transaction dates (04/16/2026 and 04/20/2026) cluster around the IPO completion, suggesting this is part of a standard executive compensation package tied to going public rather than discrete market-timing activity.

Filed: 2026-04-20

CEO Luo Yuling executed a significant equity conversion event on 04/20/2026, converting preferred stock (Class A, Founders Preferred, and Series A-1) totaling approximately 2.5 million shares into Class B Common Stock immediately prior to the company's IPO, indicating completion of the initial public offering.
The filing shows substantial direct ownership by the reporting person of approximately 1.94 million Common Stock shares and 1.50 million Class B shares, plus indirect holdings through spouse of 1.22 million Class B shares, demonstrating strong insider commitment to the company post-IPO.
CEO received a grant of 76,509 restricted stock units (RSUs) vesting monthly from grant date, alongside numerous stock options with exercise prices ranging from $1.53 to $7.60 and expiration dates extending to 2036, indicating ongoing equity compensation tied to continued service.
The magnitude of equity conversions and the complexity of the cap table restructuring during IPO suggest this company completed its transition from private to public status, with the CEO maintaining substantial founder/controlling shareholder status post-IPO.

Filed: 2026-04-20

Chen Shiping, COO and Director, acquired 760,105 shares of Common Stock through multiple transactions on 04/20/2026, including conversion of preferred shares and grant of 37,220 RSUs, indicating significant insider stake-building around the IPO completion.
The filing reflects an IPO event with automatic conversion of Class A Common Stock, Founders Preferred Stock, and Series A-1 Preferred Stock into Common Stock immediately prior to the offering, suggesting the company recently went public.
Shiping received substantial equity compensation including stock options at $17/share (163,358 shares) vesting over 4 years with a 25% cliff, plus additional options at $3.34 and $7.60 exercise prices, demonstrating substantial retention incentives aligned with long-term value creation.
The timing and scale of insider transactions (720k+ shares) combined with newly granted RSUs and options suggest leadership confidence in the post-IPO business trajectory and commitment to the company's growth.

Filed: 2026-04-20

Timothy White, President of Alamar Biosciences, converted 454,583 Class B Common Stock shares into Common Stock on 04/20/2026, immediately prior to the company's IPO, indicating completion of a major corporate milestone.
White received a significant equity grant of 37,220 restricted stock units (RSUs) vesting monthly, alongside substantial stock option grants totaling approximately 730,000 shares across multiple tranches with exercise prices ranging from $0.59 to $7.60, demonstrating strong executive retention incentives tied to the IPO.
The wide range of option exercise prices ($0.59 to $7.60) and vesting schedules spanning 2024-2026 suggest multiple rounds of equity compensation, with fully vested options at $0.59 indicating either earlier grants or potential pre-IPO valuation adjustments.
All reported transactions occurred on or around the IPO date (04/16/2026-04/20/2026), with no insider selling activity, which is a positive signal of management confidence in post-IPO performance.

Filed: 2026-04-20

Director Witney Frank received three tranches of stock options totaling 206,781 shares with exercise prices of $0.59, $3.10, and $7.60, suggesting the company's valuation has increased significantly since earlier option grants.
The $0.59 exercise price options are fully vested as of April 20, 2026, while other grants have staggered vesting schedules extending to 2035 and 2036, indicating a retention structure for long-term commitment.
Class B Common Stock was reclassified to Common Stock immediately prior to the IPO completion, reflecting Alamar Biosciences' recent transition to public markets on or around this filing date.
All options were granted on 04/20/2026 with zero dollar pricing for the derivative securities themselves, indicating these are compensation grants rather than open market transactions.

Filed: 2026-04-20

Rebecca Chambers, a Director at Alamar Biosciences, received 140,612 stock options with a strike price of $7.60 on April 20, 2026, coinciding with the company's IPO completion.
The options vest over 4 years with 25% vesting on January 15, 2027, and remaining shares vesting monthly thereafter, indicating standard post-IPO equity compensation for board members.
Class B Common Stock was reclassified to Common Stock immediately prior to the IPO completion, suggesting the conversion of founder/early investor shares to standard post-IPO share structure.
No actual stock purchases were made; this transaction represents option grants rather than insider buying, which is neutral for assessing insider confidence in current valuation.

Filed: 2026-04-20

Multiple Illumina Innovation Fund entities and Nicholas Naclerio converted significant preferred stock holdings into common stock on 04/20/2026, coinciding with ALMR's IPO closing, representing a major capitalization event for the company.
Illumina-affiliated entities hold substantial equity positions totaling approximately 5.5 million common shares plus convertible notes worth $5-3.9 million, indicating strong institutional backing from a major genomics company investor.
The conversion transactions include convertible promissory notes that automatically converted at 85% of the IPO price, suggesting favorable financing terms and confidence in the company's valuation at the time of going public.
Nicholas Naclerio maintains control over multiple fund entities as sole managing member, consolidating voting and dispositive power over tens of millions of shares worth of beneficial ownership in the newly public company.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.